| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $0 and sold $0 worth of Astria Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $17.2M and sold $247,303 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.
| 2024-04-01 | Sale | Morabito Christopher | Chief Medical Officer | 10,000 0.0183% | $13.59 | $135,939 | -28.57% | |
| 2024-02-01 | PERCEPTIVE ADVISORS LLC | director | 2.48M 5.6893% | $12.09 | $30M | -19.99% | ||
| 2024-01-29 | Sale | Morabito Christopher | Chief Medical Officer | 9,200 0.0208% | $11.15 | $102,552 | -8.93% | |
| 2024-01-26 | Sale | Morabito Christopher | Chief Medical Officer | 800 0.0022% | $11.02 | $8,812 | +2.98% | |
| 2023-12-21 | PERCEPTIVE ADVISORS LLC | director | 740,000 2.0257% | $6.20 | $4.59M | +77.37% | ||
| 2023-10-16 | PERCEPTIVE ADVISORS LLC | director | 1.07M 3.9128% | $6.51 | $7M | +56.68% | ||
| 2022-12-19 | PERCEPTIVE ADVISORS LLC | director | 908,265 6.1619% | $11.01 | $10M | -11.17% | ||
| 2021-11-19 | Komjathy Andrew | Chief Commercial Officer | 100 0.0008% | $6.70 | $670 | -6.97% | ||
| 2015-06-30 | SVLSF V, LLC | 10 percent owner | 391,090 2.5125% | $12.00 | $4.69M | -41.69% | ||
| 2015-06-30 | GALAKATOS NICHOLAS | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | |||
| 2015-06-30 | Clarus Lifesciences II, L.P. | 10 percent owner | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | ||
| 2015-06-30 | MedImmune Ventures, Inc. | 10 percent owner | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | ||
| 2015-06-30 | Laufer Ron | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | |||
| 2015-06-30 | George Jean | director | 258,776 1.6625% | $12.00 | $3.11M | -41.69% |
| PERCEPTIVE ADVISORS LLC | director | 4873721 8.6361% | $20.91M | 4 | 0 | +25.72% |
| SVLSF V, LLC | 10 percent owner | 2798528 4.9589% | $12.01M | 1 | 0 | |
| GALAKATOS NICHOLAS | 2752488 4.8773% | $11.81M | 1 | 0 | ||
| Clarus Lifesciences II, L.P. | 10 percent owner | 2752488 4.8773% | $11.81M | 1 | 0 | |
| MedImmune Ventures, Inc. | 10 percent owner | 1632652 2.893% | $7M | 1 | 0 | |
| Laufer Ron | 1632652 2.893% | $7M | 1 | 0 | ||
| George Jean | director | 1133943 2.0093% | $4.86M | 1 | 0 | |
| Komjathy Andrew | Chief Commercial Officer | 100 0.0002% | $429.00 | 1 | 0 | <0.0001% |
| Morabito Christopher | Chief Medical Officer | 0 0% | $0 | 0 | 3 |
$99,438,720 | 81 | 6.74% | $283.78M | |
$144,247,213 | 29 | 10.15% | $255.02M | |
$56,550,550 | 22 | 50.17% | $275.11M | |
$2,484,989 | 17 | -17.86% | $236.55M | |
$1,345,573 | 16 | 15.45% | $230.05M | |
$276,750,010 | 16 | -7.95% | $255.88M | |
$3,232,510 | 15 | -2.42% | $268.22M | |
$57,263,116 | 11 | -8.37% | $253.73M | |
$58,981,940 | 10 | 32.58% | $230.4M | |
$334,190 | 8 | 33.75% | $232.23M | |
$14,995,689 | 8 | 3.76% | $261.67M | |
$8,286,963 | 6 | 3.09% | $225.64M | |
Astria Therapeutics, Inc. (ATXS) | $51,588,185 | 5 | 19.18% | $242.1M |
$79,238,118 | 4 | -26.47% | $228.67M | |
$12,010,220 | 4 | -72.15% | $225.65M | |
$58,352 | 4 | -43.78% | $262.5M | |
$4,888,000 | 3 | -20.50% | $230.77M | |
$879,499 | 1 | 28.50% | $234.66M | |
$102,796 | 1 | -21.40% | $248.18M |
| Increased Positions | 56 | +44.09% | 3M | +5.16% |
| Decreased Positions | 50 | -39.37% | 3M | -5.43% |
| New Positions | 20 | New | 596,189 | New |
| Sold Out Positions | 15 | Sold Out | 422,644 | Sold Out |
| Total Postitions | 133 | +4.72% | 58M | -0.27% |
| Fmr Llc | $41,935.00 | 13.97% | 7.82M | +1,454 | +0.02% | 2024-12-31 |
| Perceptive Advisors Llc | $34,762.00 | 11.58% | 6.49M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $27,364.00 | 9.12% | 5.11M | 0 | 0% | 2024-12-31 |
| Vestal Point Capital, Lp | $22,405.00 | 7.46% | 4.18M | +180,000 | +4.5% | 2024-12-31 |
| Blackrock, Inc. | $20,521.00 | 6.84% | 3.83M | -68,395 | -1.75% | 2025-03-31 |
| Fairmount Funds Management Llc | $19,050.00 | 6.35% | 3.55M | 0 | 0% | 2024-12-31 |
| Fcpm Iii Services B.V. | $15,397.00 | 5.13% | 2.87M | +3M | New | 2024-12-31 |
| Tcg Crossover Management, Llc | $14,804.00 | 4.93% | 2.76M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $14,351.00 | 4.78% | 2.68M | +41,833 | +1.59% | 2024-12-31 |
| Vr Adviser, Llc | $13,171.00 | 4.39% | 2.46M | -1M | -28.95% | 2024-12-31 |